Avidity Biosciences (Nasdaq:RNA) - Cotización, noticias y análisis

Resumen de acción RNA

Avidity Biosciences, Inc. es una empresa biofarmacéutica dedicada a la administración de terapias de ARN.

RNA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 66.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 59.07%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Avidity Biosciences, Inc.

Myriad Genetics

NasdaqGS:MYGN

US$2.3b

Denali Therapeutics

NasdaqGS:DNLI

US$2.6b

Intellia Therapeutics

NasdaqGM:NTLA

US$2.4b

Kymera Therapeutics

NasdaqGM:KYMR

US$2.3b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Avidity Biosciences
Historical stock prices
Current Share Price	US$25.96
52 Week High	US$27.66
52 Week Low	US$4.83
Beta	0.79
1 Month Change	7.76%
3 Month Change	78.54%
1 Year Change	134.08%
3 Year Change	27.13%
5 Year Change	n/a
Change since IPO	-8.91%

Noticias y actualizaciones recientes

Recent updates

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans

Jun 07

Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Feb 22

Avidity Biosciences Has A Promising RNA Therapy Platform

Jan 13

Avidity inks research deal with Bristol Myers' subsidiary, gives 2021 pipeline updates

Jan 08

Rentabilidad de los accionistas

	RNA	US Biotechs	Mercado US
7D	-1.9%	-1.3%	1.6%
1Y	134.1%	3.0%	26.3%

Rentabilidad vs. Industria: RNA superó al sector US Biotechs , que obtuvo un rendimiento del -2.3% el año pasado.

Rentabilidad vs. Mercado: RNA superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	10.5%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de RNA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de RNA (11%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2012	253	Sarah Boyce	www.aviditybiosciences.com

Avidity Biosciences, Inc. es una empresa biofarmacéutica dedicada a la administración de terapias de ARN. Desarrolla conjugados de anticuerpos y oligonucleótidos (AOC) diseñados para tratar enfermedades que antes no podían tratarse con terapias de ARN. El principal producto candidato de la empresa es el AOC 1001 para el tratamiento de la distrofia miotónica de tipo 1, una rara enfermedad muscular monogénica que se encuentra en fase 1/2 de ensayo clínico.

Resumen de fundamentos de Avidity Biosciences, Inc.

¿Cómo se comparan los beneficios e ingresos de Avidity Biosciences con su capitalización de mercado?
Estadísticas fundamentales de RNA
Capitalización bursátil	US$2.48b
Beneficios(TTM)	-US$228.68m
Ingresos (TTM)	US$10.87m

228.4x

Ratio precio-ventas (PS)

-10.9x

Ratio precio-beneficio (PE)

¿Está RNA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de RNA
Ingresos	US$10.87m
Coste de los ingresos	US$190.97m
Beneficio bruto	-US$180.10m
Otros gastos	US$48.58m
Beneficios	-US$228.68m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.39
Margen bruto	-1,656.84%
Margen de beneficio neto	-2,103.78%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado RNA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción RNA

Recompensas

Análisis de riesgos

Competidores de Avidity Biosciences, Inc.

NasdaqGS:MYGN

US$2.3b

NasdaqGS:DNLI

US$2.6b

NasdaqGM:NTLA

US$2.4b

NasdaqGM:KYMR

US$2.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Growth Index

Avidity Biosciences, Inc. Supports World Facioscapulohumeral Muscular Dystrophy Day and Presents Preclinical Data from FSHD Program

Consensus forecasts updated

Price target decreased to US$45.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avidity Biosciences, Inc., Annual General Meeting, Jun 15, 2022